|Bid||47.50 x 200|
|Ask||50.00 x 200|
|Day's Range||48.84 - 49.42|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.69|
|Dividend & Yield||1.64 (3.39%)|
|1y Target Est||N/A|
Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.
Phase 3 trials of Alnylam's patisiran were a success, paving the way to an FDA filing for approval later this year.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were skyrocketing Wednesday as the company unveiled the latest results of one of its drugs. The pharmaceutical company revealed how well the phase 3 clinical trial of patisiran went, which is Alnylam’s lead drug that is designed to treat a rare nerve disorder that’s known as familial amyloid polyneuropathy (FAP). The safety profile of patisiran looks clean, which is perhaps even more important than the positive results as some of the company’s other pipeline drugs raised concerns regarding the toxicity levels they contained.